Encephalopathy - Pipeline Review, H2 2019
Encephalopathy - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Pipeline Review, H2 2019, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.
Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 2, 2, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Pipeline Review, H2 2019, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.
Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 2, 2, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Encephalopathy - Overview
Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalopathy - Companies Involved in Therapeutics Development
BrainRepair UG
Celularity Inc
GW Pharmaceuticals Plc
Hope Biosciences LLC
Inflazome Ltd
JS Genetics Inc
Mesoblast Ltd
Mithra Pharmaceuticals SA
Orphan Star Therapeutics LLC
Pfizer Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
SL Bigen Inc
Worphmed Srl
Encephalopathy - Drug Profiles
Alda-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diazoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target SLC2A1 for Glut1 Deficiency Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWP-42003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IL-2 for Encephalopathy, Graft Versus Host Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Target Complement C1q for Acute Intravascular Hemolytic Transfusion and Hypoxic-ischemic Encephalopathy Reaction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Target Complement C1q for Hypoxic-ischemic Encephalopathy, Infectious Diseases and Systemic Lupus Erythematosus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PSC-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remestemcel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLBM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalopathy - Dormant Projects
Encephalopathy - Discontinued Products
Encephalopathy - Product Development Milestones
Featured News & Press Releases
Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy
Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Encephalopathy - Overview
Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalopathy - Companies Involved in Therapeutics Development
BrainRepair UG
Celularity Inc
GW Pharmaceuticals Plc
Hope Biosciences LLC
Inflazome Ltd
JS Genetics Inc
Mesoblast Ltd
Mithra Pharmaceuticals SA
Orphan Star Therapeutics LLC
Pfizer Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
SL Bigen Inc
Worphmed Srl
Encephalopathy - Drug Profiles
Alda-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diazoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target SLC2A1 for Glut1 Deficiency Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWP-42003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IL-2 for Encephalopathy, Graft Versus Host Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Target Complement C1q for Acute Intravascular Hemolytic Transfusion and Hypoxic-ischemic Encephalopathy Reaction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Target Complement C1q for Hypoxic-ischemic Encephalopathy, Infectious Diseases and Systemic Lupus Erythematosus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PSC-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remestemcel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLBM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalopathy - Dormant Projects
Encephalopathy - Discontinued Products
Encephalopathy - Product Development Milestones
Featured News & Press Releases
Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy
Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Encephalopathy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Encephalopathy - Pipeline by BrainRepair UG, H2 2019
Encephalopathy - Pipeline by Celularity Inc, H2 2019
Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H2 2019
Encephalopathy - Pipeline by Hope Biosciences LLC, H2 2019
Encephalopathy - Pipeline by Inflazome Ltd, H2 2019
Encephalopathy - Pipeline by JS Genetics Inc, H2 2019
Encephalopathy - Pipeline by Mesoblast Ltd, H2 2019
Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, H2 2019
Encephalopathy - Pipeline by Orphan Star Therapeutics LLC, H2 2019
Encephalopathy - Pipeline by Pfizer Inc, H2 2019
Encephalopathy - Pipeline by ProThera Biologics Inc, H2 2019
Encephalopathy - Pipeline by ReAlta Life Sciences Inc, H2 2019
Encephalopathy - Pipeline by SL Bigen Inc, H2 2019
Encephalopathy - Pipeline by Worphmed Srl, H2 2019
Encephalopathy - Dormant Projects, H2 2019
Encephalopathy - Discontinued Products, H2 2019
Number of Products under Development for Encephalopathy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Encephalopathy - Pipeline by BrainRepair UG, H2 2019
Encephalopathy - Pipeline by Celularity Inc, H2 2019
Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H2 2019
Encephalopathy - Pipeline by Hope Biosciences LLC, H2 2019
Encephalopathy - Pipeline by Inflazome Ltd, H2 2019
Encephalopathy - Pipeline by JS Genetics Inc, H2 2019
Encephalopathy - Pipeline by Mesoblast Ltd, H2 2019
Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, H2 2019
Encephalopathy - Pipeline by Orphan Star Therapeutics LLC, H2 2019
Encephalopathy - Pipeline by Pfizer Inc, H2 2019
Encephalopathy - Pipeline by ProThera Biologics Inc, H2 2019
Encephalopathy - Pipeline by ReAlta Life Sciences Inc, H2 2019
Encephalopathy - Pipeline by SL Bigen Inc, H2 2019
Encephalopathy - Pipeline by Worphmed Srl, H2 2019
Encephalopathy - Dormant Projects, H2 2019
Encephalopathy - Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development for Encephalopathy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
BrainRepair UG
Celularity Inc
GW Pharmaceuticals Plc
Hope Biosciences LLC
Inflazome Ltd
JS Genetics Inc
Mesoblast Ltd
Mithra Pharmaceuticals SA
Orphan Star Therapeutics LLC
Pfizer Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
SL Bigen Inc
Worphmed Srl
Number of Products under Development for Encephalopathy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
BrainRepair UG
Celularity Inc
GW Pharmaceuticals Plc
Hope Biosciences LLC
Inflazome Ltd
JS Genetics Inc
Mesoblast Ltd
Mithra Pharmaceuticals SA
Orphan Star Therapeutics LLC
Pfizer Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
SL Bigen Inc
Worphmed Srl
